DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
- Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery
- Project will analyse hundreds of essential TB proteins at proteome scale, demonstrating Dalton’s ability to tackle complex scientific challenges
- Collaboration with Ersilia will make findings accessible to researchers across the Global South
London, UK – 15 October 2026 – DaltonTx, the decision engine for drug discovery, today announces that it has been awarded a grant by the Gates Foundation to advance tuberculosis (TB) drug discovery programmes using its AI-enabled platform, Dalton.
